Azilsartan: Current Evidence and Perspectives in Management of Hypertension

Figure 3

Head-to-head comparison of azilsartan and other RAAS blockers in clinical studies for reduction in 24-hour mean systolic blood pressure (SBP, as measured by ambulatory BP monitoring) from baseline. RAAS blockers used as a comparator arm in various studies were as follows: White et al., valsartan 320 mg (purple bar) and olmesartan 40 mg (green bar); Bonner et al., ramipril 10 mg; Bakris et al., olmesartan 40 mg; Sica et al., valsartan 320 mg; Rakugi et al., candesartan.